FI3722291T3 - Indolinoniyhdisteitä ja niiden käyttö fibroottisten sairauksien hoitamisessa - Google Patents
Indolinoniyhdisteitä ja niiden käyttö fibroottisten sairauksien hoitamisessa Download PDFInfo
- Publication number
- FI3722291T3 FI3722291T3 FIEP20162043.2T FI20162043T FI3722291T3 FI 3722291 T3 FI3722291 T3 FI 3722291T3 FI 20162043 T FI20162043 T FI 20162043T FI 3722291 T3 FI3722291 T3 FI 3722291T3
- Authority
- FI
- Finland
- Prior art keywords
- formula
- compound
- cycloalkyl
- salt
- alkyl
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 6
- 230000003176 fibrotic effect Effects 0.000 title claims 6
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 35
- 229910052799 carbon Inorganic materials 0.000 claims 34
- 150000003839 salts Chemical class 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 238000000034 method Methods 0.000 claims 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical class 0.000 claims 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 4
- 230000007882 cirrhosis Effects 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 201000000306 sarcoidosis Diseases 0.000 claims 4
- 125000001931 aliphatic group Chemical group 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000033116 Asbestos intoxication Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 201000010001 Silicosis Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 206010003441 asbestosis Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 238000010511 deprotection reaction Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000001848 dysentery Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 201000009890 sinusitis Diseases 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 208000029771 childhood onset asthma Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 claims 1
- 229960004378 nintedanib Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 claims 1
- 229960003073 pirfenidone Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Otolaryngology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15202764 | 2015-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3722291T3 true FI3722291T3 (fi) | 2023-09-05 |
Family
ID=55068868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP20162043.2T FI3722291T3 (fi) | 2015-12-24 | 2016-12-23 | Indolinoniyhdisteitä ja niiden käyttö fibroottisten sairauksien hoitamisessa |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US11046672B2 (enExample) |
| EP (2) | EP3394048B1 (enExample) |
| JP (1) | JP7068172B2 (enExample) |
| KR (1) | KR20180128390A (enExample) |
| CN (1) | CN109302846B (enExample) |
| AU (1) | AU2016376011B2 (enExample) |
| BR (1) | BR112018013033A2 (enExample) |
| CA (1) | CA3009778A1 (enExample) |
| CL (1) | CL2018001742A1 (enExample) |
| CO (1) | CO2018007663A2 (enExample) |
| DK (1) | DK3722291T3 (enExample) |
| EA (1) | EA038796B1 (enExample) |
| ES (2) | ES2956820T3 (enExample) |
| FI (1) | FI3722291T3 (enExample) |
| HR (1) | HRP20230833T1 (enExample) |
| HU (1) | HUE062784T2 (enExample) |
| IL (1) | IL260221A (enExample) |
| LT (1) | LT3722291T (enExample) |
| MX (1) | MX379859B (enExample) |
| MY (1) | MY195904A (enExample) |
| PH (1) | PH12018501575A1 (enExample) |
| PL (1) | PL3722291T3 (enExample) |
| PT (1) | PT3722291T (enExample) |
| RS (1) | RS64703B1 (enExample) |
| SG (1) | SG11201805423TA (enExample) |
| SI (1) | SI3722291T1 (enExample) |
| SM (1) | SMT202300260T1 (enExample) |
| WO (1) | WO2017109513A1 (enExample) |
| ZA (1) | ZA201804950B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102733897B1 (ko) | 2015-12-24 | 2024-11-22 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Cftr 조절제 및 이의 사용방법 |
| EP3426649B1 (en) * | 2016-03-08 | 2020-07-22 | Respivert Limited | Indole derivatives and their use as protein kinase inhibitors |
| US11839616B2 (en) | 2017-08-24 | 2023-12-12 | The Regents Of The University Of California | Ocular pharmaceutical compositions |
| CN109678810B (zh) * | 2019-01-23 | 2022-10-28 | 南京工业大学 | 一种1,2-氧氮杂环丁烷类化合物及其制备方法与应用 |
| CA3159601A1 (en) * | 2019-11-20 | 2021-05-27 | Angion Biomedica Corp. | Methods for treating inflammatory bowel disease |
| CN111789842B (zh) * | 2020-08-07 | 2021-09-21 | 南开大学 | 尼达尼布在制备用于治疗炎症性肠病的药物中的应用 |
| KR102739882B1 (ko) * | 2021-04-02 | 2024-12-06 | 연세대학교 원주산학협력단 | 로베글리타존을 유효성분으로 하는 안과질환 치료용 조성물 |
| CN113200936B (zh) * | 2021-05-19 | 2022-10-21 | 南京工业大学 | 10-甲基吩噁嗪衍生物、其锆金属有机框架材料及制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA75054C2 (uk) | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| DE10117204A1 (de) | 2001-04-06 | 2002-10-10 | Boehringer Ingelheim Pharma | In 6-Stellung substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| JP2004182726A (ja) * | 2002-11-22 | 2004-07-02 | Yamanouchi Pharmaceut Co Ltd | ２−オキソインドリン誘導体 |
| US20060154939A1 (en) | 2004-12-24 | 2006-07-13 | Boehringer Ingelheim International Gmbh | Medicaments for the Treatment or Prevention of Fibrotic Diseases |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| US7692005B2 (en) * | 2005-07-13 | 2010-04-06 | Allergan, Inc. | Kinase inhibitors |
| EP2303841A1 (en) | 2008-07-14 | 2011-04-06 | Gilead Sciences, Inc. | Oxindolyl inhibitor compounds |
| EP3426649B1 (en) | 2016-03-08 | 2020-07-22 | Respivert Limited | Indole derivatives and their use as protein kinase inhibitors |
-
2016
- 2016-12-23 HR HRP20230833TT patent/HRP20230833T1/hr unknown
- 2016-12-23 CN CN201680082097.2A patent/CN109302846B/zh not_active Expired - Fee Related
- 2016-12-23 KR KR1020187020374A patent/KR20180128390A/ko not_active Withdrawn
- 2016-12-23 PT PT201620432T patent/PT3722291T/pt unknown
- 2016-12-23 ES ES20162043T patent/ES2956820T3/es active Active
- 2016-12-23 DK DK20162043.2T patent/DK3722291T3/da active
- 2016-12-23 FI FIEP20162043.2T patent/FI3722291T3/fi active
- 2016-12-23 MY MYPI2018001087A patent/MY195904A/en unknown
- 2016-12-23 JP JP2018533630A patent/JP7068172B2/ja active Active
- 2016-12-23 BR BR112018013033A patent/BR112018013033A2/pt not_active Application Discontinuation
- 2016-12-23 HU HUE20162043A patent/HUE062784T2/hu unknown
- 2016-12-23 SI SI201631745T patent/SI3722291T1/sl unknown
- 2016-12-23 EP EP16820318.0A patent/EP3394048B1/en active Active
- 2016-12-23 SM SM20230260T patent/SMT202300260T1/it unknown
- 2016-12-23 US US16/066,043 patent/US11046672B2/en not_active Expired - Fee Related
- 2016-12-23 RS RS20230860A patent/RS64703B1/sr unknown
- 2016-12-23 ES ES16820318T patent/ES2796358T3/es active Active
- 2016-12-23 CA CA3009778A patent/CA3009778A1/en not_active Abandoned
- 2016-12-23 AU AU2016376011A patent/AU2016376011B2/en not_active Ceased
- 2016-12-23 EA EA201891506A patent/EA038796B1/ru unknown
- 2016-12-23 MX MX2018007852A patent/MX379859B/es unknown
- 2016-12-23 EP EP20162043.2A patent/EP3722291B1/en active Active
- 2016-12-23 PL PL20162043.2T patent/PL3722291T3/pl unknown
- 2016-12-23 WO PCT/GB2016/054069 patent/WO2017109513A1/en not_active Ceased
- 2016-12-23 LT LTEP20162043.2T patent/LT3722291T/lt unknown
- 2016-12-23 SG SG11201805423TA patent/SG11201805423TA/en unknown
-
2018
- 2018-06-24 IL IL260221A patent/IL260221A/en unknown
- 2018-06-25 CL CL2018001742A patent/CL2018001742A1/es unknown
- 2018-07-23 ZA ZA201804950A patent/ZA201804950B/en unknown
- 2018-07-24 CO CONC2018/0007663A patent/CO2018007663A2/es unknown
- 2018-07-24 PH PH12018501575A patent/PH12018501575A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3722291T3 (fi) | Indolinoniyhdisteitä ja niiden käyttö fibroottisten sairauksien hoitamisessa | |
| JP2015522036A5 (enExample) | ||
| HRP20200538T1 (hr) | Derivati pirimidina za liječenje virusnih infekcija | |
| JP2016523906A5 (enExample) | ||
| JP2020530487A5 (enExample) | ||
| MY176210A (en) | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine | |
| PE20161475A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
| JP2016510323A5 (enExample) | ||
| EA201990688A1 (ru) | Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение | |
| JP2010536887A5 (enExample) | ||
| MX380516B (es) | Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico | |
| HRP20191431T1 (hr) | Postupak za pripravu (4s)-4-(4-cijano-2-metoksifenil)-5-etoksi-2,8-dimetil-1,4-dihidro-1-6- naftiridin-3-karboksamida i njegovo pročišćavanje za uporabu kao aktivni farmaceutski pripravak | |
| HRP20211223T1 (hr) | Heterociklički indoli za upotrebu kod infekcije virusom influence | |
| JP2016537346A5 (enExample) | ||
| MA39866A (fr) | Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle | |
| AU2021367554B2 (en) | Deuterated hpk1 kinase inhibitor, and preparation method therefor and use thereof | |
| EA201590021A1 (ru) | Новые замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные гетероциклами, в качестве противовирусных средств против респираторного синцитиального вируса | |
| PH12013500105A1 (en) | Process for preparing antiviral compounds | |
| TN2019000204A1 (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| JP2019501910A5 (enExample) | ||
| JP2017531663A5 (enExample) | ||
| JP2017537937A5 (enExample) | ||
| SI3102573T1 (en) | SUBSTITUTED TIAZOL OR OXASOL AS ANTAGONISTS OF THE RECEPTOR P2X7 | |
| CN112771045A (zh) | 喹啉并吡咯烷-2-酮类衍生物及其应用 | |
| MX2021011971A (es) | Proceso para preparar cicloserinas sustituidas. |